Alkermes (ALKS) EBIT (2010 - 2026)
Alkermes' (ALKS) quarterly EBIT came in at -$48.3 million in Q1 2026, down 450.06% year-on-year from $13.8 million in Q1 2025, and down 183.09% on a QoQ basis from $58.1 million in Q4 2025.
Alkermes (ALKS) EBIT (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of EBIT data on file, last reported at -$48.3 million in Q1 2026.
- On a quarterly basis, EBIT fell 450.06% year-over-year to -$48.3 million in Q1 2026; TTM through Mar 2026 was $191.9 million, a 50.94% decrease from a year earlier, with the FY2025 full-year figure at $254.0 million, down 39.63% from the prior year.
- EBIT for Q1 2026 stood at -$48.3 million, down from $58.1 million in the prior quarter.
- Over the last five years, EBIT for ALKS reached as high as $281.3 million in Q2 2023 and fell as low as -$60.6 million in Q3 2022.
- Historically, EBIT has averaged $60.8 million across 5 years, with a median of $58.1 million in 2025.
- Across the five-year window, EBIT tumbled 879.39% in 2022 and jumped 916.29% in 2023, its largest moves.
- Year by year, EBIT stood at $115.6 million in 2022, then slumped by 52.74% to $54.6 million in 2023, then soared by 197.79% to $162.7 million in 2024, then slumped by 64.29% to $58.1 million in 2025, then slumped by 183.09% to -$48.3 million in 2026.
- Per Business Quant data, the three most recent EBIT figures were -$48.3 million in Q1 2026, $58.1 million in Q4 2025, and $89.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -48.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.28 Mn |
| Dec 31, 2025 | 58.10 Mn |
| Sep 30, 2025 | 89.08 Mn |
| Jun 30, 2025 | 92.98 Mn |
| Mar 31, 2025 | 13.79 Mn |
| Dec 31, 2024 | 162.69 Mn |
| Sep 30, 2024 | 104.76 Mn |
| Jun 30, 2024 | 109.88 Mn |
| Mar 31, 2024 | 43.31 Mn |
| Dec 31, 2023 | 54.63 Mn |
| Sep 30, 2023 | 89.19 Mn |
| Jun 30, 2023 | 281.27 Mn |
| Mar 31, 2023 | -10.97 Mn |
| Dec 31, 2022 | 115.59 Mn |
| Sep 30, 2022 | -60.64 Mn |
| Jun 30, 2022 | -34.46 Mn |
| Mar 31, 2022 | -26.59 Mn |
| Dec 31, 2021 | 129.42 Mn |
| Sep 30, 2021 | -19.66 Mn |
| Jun 30, 2021 | 4.42 Mn |